

Epidemiology and Ultrasound screening of NTD in France.



*Romain Favre
CMCO-HUS
Strasbourg France*

Plan


- Recent published epidemiological data in France
- Analysis of the activity in our Fetal Medicine center of CMCO in Strasbourg
- Influence of the loss of the MSS of Down syndrome in the second trimester (α foeto-protein)
- Evolution of the prenatal Screening strategy

Epidemiological datas

- **Retrospective study from data of the Registry of Congenital Malformations of Alsace between 1995 and 2009.**
- **23.000 births per year, Total of 192.321 births**
- **272 cases of NTD – Prevalence 12/10.000**
 - **113 Anencephaly (41 %)**
 - **35 Cephaloceles (13 %)**
 - **124 Spina bifida (46 %)**


Epidemiological datas

Evolution between 1995 and 2009.




Epidemiological datas

Percentage of prenatal diagnosis between 1995 and 2009.




Epidemiological datas

Gestational age of prenatal diagnosis between 1995 and 2009.




Epidemiological data

Outcome of spina bifida.




Data from CMCO

- Retrospective study from data of the Prenatal Registry of the Fetal Medicine dept. between 2000 and 2014.
- Total of 69.754 Fetal Ultrasound
- 239 cases of NTD



Data from CMCO

- Evolution of the gestational age at diagnosis



Data from CMCO


- Maternal age : 29.9 ± 5.7 (15 – 43)
- Gestational age : 22.4 ± 6.1 (12 – 38)
 - < 15 week's 34 (14.2 %)
 - 16 – 20 52 (21.8 %)
 - 21 – 26 103 (43 %)
 - > 26 50 (20.9 %)
- Singleton : 228 (95 %)
- Twin : 11 (4.6 %)
- Fetal Caryotype
 - Normal 154 (90,5 %)
 - Trisomy 18 11 (6.5 %)
 - Triploidy 3 (1.8 %)
 - Structure abn. 2 (1.2 %)
- Ultrasound aspect :
 - Ventriculomegaly 90 (38 %)
 - Club foot 38 (16 %)
 - Syndrom 28 (11 %)

Outcome:

- TOP 178
- STB 6
- Live births 42 (17 %)
- Loss 13
- Neonatal death 13


Data from CMCO

- Evolution of the outcome



Epidemiological datas

Evolution of the Neurosurgical activity between 1994 and 2010.




Impact of the loss of AFP

Objective: Evolution of the rate of prenatal diagnosis of spina bifida after the national modification of the use of the 2nd trimester MSS toward the 1st trimester.

- **Retrospective study from 2009 and 2011.**
 - **Comparison:**
 - 2009: AFP with the 2nd trimester MSS
 - 2010 : Transitional period
 - 2011 : No AFP, because of the use of 1st trimester MSS
- **858 spina bifida – 190 loss to follow up**
- **Maternal age : 29 [15 – 52]**
 - Previous NTD : 36
 - Maternal Epilepsy : 13
 - Diabetes : 9
 - Obesity (BMI > 35) : 58
- **Aneuploidy : 25 (2.9 %)**
- **Syndrom : 141 (16.4 %)**
- **Isolated Spina bifida : 607**



Impact of the loss of AFP



Impact of the loss of AFP


ETUDE COLLABORATIVE SPINALPHA

Isabelle CZERKIEWICZ
Emmanuel SPAGGIARI
Alexandra SEGONNE
Sophie DREUX
Françoise MULLER

Fédérations des CPOPN
ABA
Société Française de Neurochirurgie Pédiatrique
Fédération des Réseaux de Périnatalité
SOFPOET

Unité de Bioscience Fœtale
Hôpital Robert Debré, Paris





Gestational age at diagnosis

- **Group without AFP or normal AFP (n = 131 + 290).**
 - 14 – 20⁺⁶ : n = 69 (16.3 %)
 - 21 – 26 : n = 307 **(73 %)**
 - > 26 : n = 36 (8.5 %)
- **Group with AFP and AFP > 2.5 MoM (n = 186).**
 - 14 – 20⁺⁶ : n = 120 **(64.5 %)**
 - 21 – 26 : n = 60 (32.2 %)
 - > 26 : n = 6 (3.2 %)





Outcome


Live births : 70 (8.3 %) 1 FN at ultrasound

TOP : 768 (92.3 %)

Fetal loss : 4 (0.5 %)

Syndrom : 166 98 % TOP


Prenatal screening



Prenatal diagnosis



Prenatal screening





ETUDE PRIUM : RÉPARATION PRÉNATALE DES MYÉLOMÉNINGOCÈLES

Investigateur coordonnateur : Pr Jean-Marie JOUANNIC

Responsable Scientifique : Pr Michel ZERAH

Chef de Projet URC Paris Necker-Cochin : Laurence Lecomte

Attachée de Recherche Clinique URC Paris Necker-Cochin : Elsa Bournaud

Statisticien : Pr Jean-Marc TRELUYER, Hôpital Necker

Évaluateur : Assistance Publique Hôpitaux de Paris

**L'AMOUR
PLUS FORT QUE LA HAÏNE**

